# A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

> **NCT01040728** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 122 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Olodaterol (BI1744) Low
- **DRUG:** Olodaterol (BI1744) High
- **DRUG:** Tiotropium 18 mcg
- **DRUG:** Placebo (for Olodaterol (BI1744)l)
- **DRUG:** Placebo (for Tiotropium)

## Key facts

- **NCT ID:** NCT01040728
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-01
- **Final completion:** —
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2014-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01040728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01040728, "A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01040728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*